Abstract: The present invention provides a composition, comprising ferrous amino acid chelate particles sintered from ferrous amino acid chelate, wherein the average particle size of the ferrous amino acid chelate particles ranges from 500 nm to 2600 nm, and the average molecular weight of the particles ranges from 1,500 Dalton to 600,000 Dalton. Besides, the present invention can be used for manufacturing a medicament for treating or ameliorating a pancreas-related disease, wherein the medicament comprises an effective amount of the composition and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g.

Abstract: A method of treating skin is disclosed. The method includes topically applying to the skin a composition comprising 0.0001 wt. % to 5 wt. % of a kakadu plum fruit extract, and 0.0001 wt. % to 5 wt. % of an acai berry fruit extract.

Abstract: A compound 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol compound, its synthesis, and its use as an anticancer, anti-inflammatory, and/or antimicrobial agent.

Abstract: The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.

Abstract: An 2-amino-4-(4-bromophenyl)-6-methoxypyridine-3,5-dicarbonitrile compound, its synthesis, and its use as an antibacterial agent.

Abstract: An 2-amino-4-(4-bromophenyl)-6-methoxypyridine-3.5-dicarbonitrile compound, its synthesis, and its use as an antibacterial agent.

Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: Disclosed herein are carborane derivatives of Formula I or Formula V, or a pharmaceutically acceptable salt thereof, for use as neuromuscular blocking agents. The carborane is substituted with two cationic functional groups selected from amines that form ammonium cations, ethers and/or alcohols that form oxonium cations, sulfides and/or thiols that form sulfonium cations, and phosphanes and/or phosphines that form phosphonium cations.

Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.

Abstract: A contraceptive regimen that provides for a reduced level of estrogen. The contraceptive regimen can be used for the treatment of symptoms associated with endometriosis or fibroids.

Abstract: External compositions containing one or more lipophilic naphthoic acid retinoid compounds are described. The external compositions are applied to skin where they stimulate skin repair and visibly improve skin damage caused by photoaging and acne.

Abstract: Described herein protein drug conjugates and compositions thereof that are useful, for example, for the target-specific delivery of drugs to cells. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced. In certain embodiments, compounds, compositions, and conjugates are provided, which include hydrophilic residues in linker-payloads and protein conjugates thereof.

Abstract: The present disclosure provides a compound of Formula (I) and/or a stereoisomer, a tautomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds. They are kinase inhibitors potentially useful in the treatment of diseases treatable, such as cancers. Also disclosed herein is a pharmaceutical composition, comprising a compound of Formula (I) and/or a stereoisomer, a tautomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Abstract: Novel pyrazino[1?,2?:1,5]pyrazolo[4,3-b][1,6]naphthyridine, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrazino[1?,2?:1,5]pyrazolo[4,3-b][1,6]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Abstract: A cosmetic composition for treating acne includes at least one acne treatment active, for example, salicylic acid or a derivative thereof, which may present in an amount that is greater than 1%, by weight, based on the weight of the sulfate-free cleansing composition, and an aqueous carrier that includes at least one surfactant selected from the group consisting of sarcosinates, betaines, and combinations thereof, at least one solubilizer comprising a polyethylene glycol compound, and water. When the sulfate-free cleansing composition is applied to a keratinous tissue it demonstrates deposition and retention of the beta hydroxy acid on the keratinous tissue after rinsing with water.

Abstract: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.

Abstract: The present disclosure relates to a novel spherical agglomeration method for proteins, and protein particles made by the spherical agglomeration method. By using continuous oscillatory baffled crystallizer, the method of the present disclosure is capable of maintain the biologically activities and providing protein particles with an average particle size between 1-500 ?m.

Abstract: Disclosed are methods of treating ataxia by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.